Duke, May 15 -- NUS Medical School (Duke-NUS), a research-intensive graduate-entry medical school, GenScript Biotech Corporation, a leading global biotechnology company, and the Diagnostics Development Hub (DxD) at Singapore's Agency for Science, Technology and Research (A*STAR), announced an exclusive agreement to co-develop and manufacture a unique serological coronavirus (COVID-19) detection system known as the surrogate virus neutralisation test (sVNT) or cPass. This test is the first in the world that allows rapid detection of neutralising antibodies (NAbs) - the specific antibodies present in the serum of COVID-19 patients that are responsible for clearing the viral infection, without the need of live biological materials and biocon...